Market Cap : 4.75 B | Enterprise Value : 4.62 B | PE Ratio : | PB Ratio : 38.39 |
---|
NAS:EIDX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NAS:EIDX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Eidos Therapeutics's Accounts Receivable for the three months ended in Sep. 2020 was $0.00 Mil. Eidos Therapeutics's Revenue for the three months ended in Sep. 2020 was $0.13 Mil. Hence, Eidos Therapeutics's days sales outstanding for the three months ended in Sep. 2020 was 0.00.
Eidos Therapeutics's days sales outstanding stayed the same from Sep. 2019 (0.00) to Sep. 2020 (0.00).
* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.
* The bar in red indicates where Eidos Therapeutics's Days Sales Outstanding falls into.
Days sales outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
Accounts Receivable can be measured by Days Sales Outstanding.
Eidos Therapeutics's Days Sales Outstanding for the fiscal year that ended in Dec. 2019 is calculated as
Days Sales Outstanding | = | Accounts Receivable | / | Revenue | * | Days in Period |
= | 0 | / | 26.691 | * | 365 | |
= | 0.00 |
Eidos Therapeutics's Days Sales Outstanding for the quarter that ended in Sep. 2020 is calculated as:
Days Sales Outstanding | = | Accounts Receivable | / | Revenue | * | Days in Period |
= | 0 | / | 0.127 | * | 365 / 4 | |
= | 0.00 |
* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
No Headline